RMG Wealth Management’s X4 Pharmaceuticals XFOR Stock Holding History

RMG Wealth Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28	Closed	-$64	–	660
2025 Q4	$64	Buy	+28	New	+$102	﹤0.01%	412

Other funds holding XFOR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

RMG Wealth Management's XFOR Position: Q1 2026 in Review

RMG Wealth Management sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 28 shares — an estimated $64 sold.

RMG Wealth Management first reported a position in XFOR in Q4 2025 and held it in 1 quarter. The position peaked at $64 in Q4 2025. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

RMG Wealth Management reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
RMG Wealth Management sold 28 X4 Pharmaceuticals shares in Q1 2026, an estimated $64.
RMG Wealth Management first reported a position in X4 Pharmaceuticals in Q4 2025 and held it in 1 quarter.
RMG Wealth Management's X4 Pharmaceuticals position peaked at $64 in Q4 2025.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on RMG Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.